Related Experiment Video
Updated: Feb 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
1Department of Paediatrics and Child Health and Division of Molecular Biology and Human Genetics and the MRC Centre for Molecular and Cellular Biology, DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of Stellenbosch and Tygerberg Children's Hospital, PO Box 19063, 7505 Tygerberg, South Africa. prd@sun.ac.za
Abstract:
Tuberculous meningitis (TBM) causes a devastating morbidity and mortality in adults and children. Even in patients presenting at an early stage of disease, deterioration may occur despite apparently adequate therapy. The literature relating to cerebrospinal fluid penetration of antituberculosis agents is reviewed. Amongst the essential antituberculosis agents isoniazid has the best CSF pharmacokinetics reaching peak concentrations (C(max)) only slightly less than in blood. Pyrazinamide also has good CSF penetration and in children receiving dosages of 40 mg/kg the CSF C(max) exceeds the proposed minimal inhibitory concentration of 20 μg/ml. Streptomycin other aminoglycosides and ethambutol have poor CSF penetration and cannot be agents of first choice for TBM treatment. Rifampicin at dosages used in adults seldom reaches CSF concentrations exceeding MIC, but does so more frequently in children when dosages of up to 20 mg/kg are used. The non-essential agents ethionamide, the fluoroquinolones, with the exception of ciprofloxacin, and cycloserine (terizadone) have relatively good CSF penetration and are recommended for TBM treatment. The dosages of the essential agents recommended for the treatment of TBM in children are INH 10 mg/kg (range 6-15 mg/kg bodyweight), rifampicin 15 mg/kg (range 10-20 mg/kg), pyrazinamide 35 mg/kg (range 30-40 mg/kg), ethambutol 20 mg/kg (range 15-25 mg/kg) and streptomycin 15 mg/kg (range 12-18 mg/kg). Amongst second-line agents ofloxacin, levofloxacin and moxifloxacin should be used in dosages of 15-20 mg/kg, ethionamide 20 mg/kg in a single dose, if tolerated, and for cycloserine (terizadone) 15 mg/kg. Antituberculous chemotherapy should be started as soon as the diagnosis of TBM is considered.
Insights
Optimizing antituberculosis drug selection for tuberculous meningitis (TBM) is crucial. Isoniazid and pyrazinamide show good cerebrospinal fluid penetration, while others like streptomycin have poor penetration, impacting TBM treatment efficacy.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neurology
Background:
- Tuberculous meningitis (TBM) presents a significant global health challenge, causing severe morbidity and mortality in both children and adults.
- Despite early diagnosis and treatment, patient outcomes can be poor due to inadequate drug penetration into the cerebrospinal fluid (CSF).
Purpose of the Study:
- To review the literature on the cerebrospinal fluid (CSF) penetration of antituberculosis agents.
- To guide optimal drug selection and dosing for tuberculous meningitis (TBM) treatment based on CSF pharmacokinetics.
Main Methods:
- Systematic literature review of studies evaluating antituberculosis drug concentrations in CSF.
- Analysis of pharmacokinetic data, including peak concentrations (Cmax) and their relation to minimum inhibitory concentrations (MIC).
Main Results:
- Isoniazid demonstrates excellent CSF penetration. Pyrazinamide achieves therapeutic CSF concentrations, especially in children at recommended doses.
- Streptomycin, ethambutol, and adult-dose rifampicin exhibit poor CSF penetration, limiting their use as first-line agents.
- Non-essential agents like ethionamide, fluoroquinolones (except ciprofloxacin), and cycloserine show good CSF penetration and are recommended.
Conclusions:
- Drug selection for TBM should prioritize agents with proven CSF penetration, such as isoniazid and pyrazinamide.
- Dosage adjustments, particularly for rifampicin in children, are necessary to achieve effective CSF concentrations.
- Prompt initiation of chemotherapy with appropriate agents is vital for improving TBM patient outcomes.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

